SS Innovations International (NASDAQ:SSII) Downgraded by Wall Street Zen to "Strong Sell"

SS Innovations International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded SS Innovations International to “Strong Sell” from “Sell.” Weiss Ratings maintained its “Sell (e+)” rating, and MarketBeat data shows a consensus “Sell” rating with a $7 price target.
  • SSII opened at $1.27, near its 12-month low of $1.12, and was down 0.8%. Its recent quarter included a $0.03-per-share loss on $6.33 million in revenue.
  • CEO Sudhir Srivastava sold 33,333 shares for about $100,000, a 0.03% reduction in his holdings; several institutional investors reported initiating or increasing positions.
  • Interested in SS Innovations International? Here are five stocks we like better.

SS Innovations International (NASDAQ:SSII - Get Free Report) was downgraded by analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of SS Innovations International in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has a consensus rating of "Sell" and a consensus price target of $7.00.

Check Out Our Latest Stock Analysis on SSII

SS Innovations International Trading Down 0.8%

SSII opened at $1.27 on Friday. SS Innovations International has a 12 month low of $1.12 and a 12 month high of $6.79. The stock has a market capitalization of $254.48 million, a price-to-earnings ratio of -18.14 and a beta of -1.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.10 and a quick ratio of 1.66. The business has a fifty day moving average price of $2.44 and a 200 day moving average price of $3.65.

SS Innovations International (NASDAQ:SSII - Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $6.33 million during the quarter. SS Innovations International had a negative net margin of 31.51% and a negative return on equity of 29.51%.

Insider Buying and Selling

In other news, CEO Srivastava Sudhir sold 33,333 shares of the stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $3.00, for a total transaction of $99,999.00. Following the completion of the sale, the chief executive officer owned 108,520,928 shares in the company, valued at approximately $325,562,784. This represents a 0.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Hedge Funds Weigh In On SS Innovations International

A number of large investors have recently modified their holdings of SSII. Goldman Sachs Group Inc. purchased a new position in shares of SS Innovations International in the third quarter valued at $38,000. 71 West Capital Partners purchased a new stake in shares of SS Innovations International in the 3rd quarter worth about $596,000. Inspire Investing LLC grew its stake in SS Innovations International by 19.7% in the 3rd quarter. Inspire Investing LLC now owns 223,053 shares of the company's stock valued at $665,000 after acquiring an additional 36,756 shares during the last quarter. Finally, Eversept Partners LP grew its stake in SS Innovations International by 46.2% in the 1st quarter. Eversept Partners LP now owns 110,157 shares of the company's stock valued at $551,000 after acquiring an additional 34,799 shares during the last quarter.

SS Innovations International Company Profile

(Get Free Report)

SS Innovations International is a medical technology company focused on developing and manufacturing surgical robotic systems. Its flagship product, the SSI Mantra, is a multi-arm platform designed to support surgeons during minimally invasive procedures. The company's offerings include surgical instruments and related technologies, such as its SSI Mudra instruments, as well as training and support services for hospitals and clinicians. The SSI Mantra system is designed with features including a surgeon console and 3D visualization, and the company has also emphasized remote surgery and telementoring capabilities.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in SS Innovations International Right Now?

Before you consider SS Innovations International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SS Innovations International wasn't on the list.

While SS Innovations International currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines